Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011

Int J Cardiol. 2011 Dec:154 Suppl 1:S45-53. doi: 10.1016/S0167-5273(11)70492-2.


The 2009 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hypertension (PAH) but also some aspects of pulmonary hypertension (PH) in chronic lung disease. These guidelines point out that the drugs currently used to treat patients with PAH (prostanoids, endothelin receptor antagonists and phosphodiesterase type-5 inhibitors) have not been sufficiently investigated in other forms of PH. Therefore, the use of these drugs in patients with chronic lung disease and PH is not recommended. This recommendation, however, is not always in agreement with medical needs as physicians feel sometimes inclined to also treat other forms of pulmonary hypertension which may affect the quality of life and survival of these patients in a similar manner as in PAH. In June 2010, a consensus conference was held in Cologne, Germany, to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. The conference was sponsored by the German Society of Cardiology, the German Society of Respiratory Medicine and the German Society of Pediatric Cardiology (DGK, DGP and DGPK). To this end, a number of working groups were initiated, one of which was specifically dedicated to the diagnosis and treatment of PH due to chronic lung disease. This manuscript describes in detail the results and recommendations of this working group which were last updated in October 2011.

Publication types

  • Consensus Development Conference

MeSH terms

  • Chronic Disease
  • Germany
  • Hemodynamics
  • Humans
  • Hypertension, Pulmonary / classification
  • Hypertension, Pulmonary / diagnosis*
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / etiology
  • Lung / physiopathology*
  • Lung Diseases / complications*
  • Practice Guidelines as Topic